Jw Life Science Corp (234080) — Cash Flow-to-Debt Ratio
Jw Life Science Corp (234080) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of ₩5.08 Billion could theoretically repay 0% of its total liabilities (₩97.63 Billion) in one year. See Jw Life Science Corp free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jw Life Science Corp Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Jw Life Science Corp across 11 annual periods. Also explore Jw Life Science Corp (234080) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jw Life Science Corp (2015–2025)
Year-by-year debt coverage analysis for Jw Life Science Corp. For market capitalisation and broader financial context, see how much is Jw Life Science Corp worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | ₩40.54 Billion | ₩97.63 Billion | ▲ +2.3% |
| 2024 | 0.41x | ₩50.69 Billion | ₩124.88 Billion | ▲ +4.2% |
| 2023 | 0.39x | ₩37.57 Billion | ₩96.44 Billion | ▲ +210.5% |
| 2022 | 0.13x | ₩14.13 Billion | ₩112.61 Billion | ▼ -63.4% |
| 2021 | 0.34x | ₩30.17 Billion | ₩87.97 Billion | ▼ -36.9% |
| 2020 | 0.54x | ₩46.75 Billion | ₩85.98 Billion | ▲ +76.5% |
| 2019 | 0.31x | ₩24.28 Billion | ₩78.79 Billion | ▼ -21.9% |
| 2018 | 0.39x | ₩36.13 Billion | ₩91.60 Billion | ▲ +72.5% |
| 2017 | 0.23x | ₩22.05 Billion | ₩96.43 Billion | ▲ +45.0% |
| 2016 | 0.16x | ₩16.08 Billion | ₩101.94 Billion | ▼ -40.9% |
| 2015 | 0.27x | ₩25.90 Billion | ₩97.05 Billion | — |